Drug Type Autologous CAR-T |
Synonyms Anti-CD19 CAR T cells - Miltenyi Biotec, MB CART19.1, MB-CART19.1 |
Target |
Mechanism CD19 modulators(B-lymphocyte antigen CD19 modulators) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Systemic Lupus Erythematosus | Phase 2 | DE | Miltenyi Biomedicine GmbHStartup | 01 Mar 2024 |
Chronic Lymphocytic Leukemia | Phase 2 | US | 19 Apr 2022 | |
Chronic Lymphocytic Leukemia | Phase 2 | US | 19 Apr 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 2 | US | 19 Apr 2022 | |
Diffuse Large B-Cell Lymphoma | Phase 2 | US | 19 Apr 2022 | |
Follicular Lymphoma | Phase 2 | US | 19 Apr 2022 | |
Follicular Lymphoma | Phase 2 | US | 19 Apr 2022 | |
Lymphoplasmacytic Lymphoma | Phase 2 | US | 19 Apr 2022 | |
Lymphoplasmacytic Lymphoma | Phase 2 | US | 19 Apr 2022 | |
Mantle-Cell Lymphoma | Phase 2 | US | 19 Apr 2022 |